{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:29Z","timestamp":1790790269384,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec id=\"ab-hbr230009-4\"><jats:title>Importance<\/jats:title><jats:p>Hereditary transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure (HF) with distinct treatment. The amyloidogenic <jats:italic>pV142I<\/jats:italic> (<jats:italic>V122I)<\/jats:italic> variant is present in 3% to 4% of Black individuals in the US and increases the risk for atrial fibrillation (AF), HF, and mortality. Since hereditary transthyretin cardiac amyloidosis demonstrates age-dependent anatomic penetrance, evaluation later in life may identify survivors at particularly high risk.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-5\"><jats:title>Objective<\/jats:title><jats:p>To estimate age-dependent risks for cardiovascular events with the variant.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-6\"><jats:title>Design, Settings, and Participants<\/jats:title><jats:p>This cohort study analyzed Black participants from the Atherosclerosis Risk in Communities (ARIC) study attending visit 1 (1987-1989) (followed up until 2019; median follow-up, 27.6 years). Data analyses were completed from June 2022 to April 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-7\"><jats:title>Exposure<\/jats:title><jats:p><jats:italic>pV142I<\/jats:italic> carrier status.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-8\"><jats:title>Main outcomes<\/jats:title><jats:p>The association between the variant and AF, HF hospitalization, mortality, and a composite of HF hospitalization or mortality was modeled by generating 10-year absolute risk differences for each year between ages 53 (the median age at visit 1) and 80 years, adjusting for the first 5 principal components of ancestry and sex. As an example, 5- and 10-year risk differences were specifically estimated for the composite outcome among participants surviving to age 80 years.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-9\"><jats:title>Results<\/jats:title><jats:p>Among 3856 Black participants (including 124 carriers) at visit 1, 2403 (62%) were women, 2140 (56%) had hypertension, and 740 (20%) had diabetes, with no differences between groups. The 10-year absolute risk difference between ages 53 and 80 years increased over time for each outcome. Statistical significance for increased 10-year risk difference emerged near ages 65 years for AF, 70 years for HF hospitalization, and 75 years for mortality. Among participants surviving to age 80 years, carriers had a 20% (95% CI, 2%-37%) and 24% (95% CI, 1%-47%) absolute increased risk for HF hospitalization or death at 5 and 10 years, respectively. Thus, at age 80 years, only 4 carriers would need to be identified to attribute 1 HF hospitalization or death over the following decade to the variant.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hbr230009-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, age-specific risks were provided for relevant outcomes with the <jats:italic>pV142I<\/jats:italic> variant. Despite a relatively benign course during earlier years, Black individuals who carry the <jats:italic>pV142I<\/jats:italic> variant surviving into later life may be particularly vulnerable. These data may inform timing for screening, risk counseling to patients, and potential strategies for early targeted therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.1525","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T09:30:39Z","timestamp":1684747839000},"page":"784","source":"Crossref","is-referenced-by-count":17,"title":["Age Dependency of Cardiovascular Outcomes With the Amyloidogenic <i>pV142I<\/i> Transthyretin Variant Among Black Individuals in the US"],"prefix":"10.1001","volume":"8","author":[{"given":"Senthil","family":"Selvaraj","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Molecular Physiology Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Cristina","family":"Quarta","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals Inc, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo M.","family":"Inciardi","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel N.","family":"Buxbaum","sequence":"additional","affiliation":[{"name":"The Scripps Research Institute, La Jolla, California"},{"name":"Protego Biopharma, San Diego, California"},{"name":"The Scintillon Institute, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Mosley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amil M.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hbr230009r1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"hbr230009r2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among Black individuals.","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"hbr230009r3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly Black Americans.","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"hbr230009r4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2021.04.042","article-title":"Atrial fibrillation and ischemic stroke with the amyloidogenic V122I transthyretin variant among Black Americans.","volume":"78","author":"Selvaraj","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"hbr230009r5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry.","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"hbr230009r6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"issue":"7","key":"hbr230009r7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"hbr230009r8","first-page":"1","article-title":"Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) study.","volume":"6","author":"Sinha","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"hbr230009r9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/oxfordjournals.aje.a115184","article-title":"The Atherosclerosis Risk in Communities (ARIC) study: design and objectives.","volume":"129","author":"The ARIC investigators","year":"1989","journal-title":"Am J Epidemiol"},{"issue":"23","key":"hbr230009r10","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan.","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"10244","key":"hbr230009r11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"hbr230009r12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis.","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"hbr230009r13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"hbr230009r14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/CIRCULATIONAHA.122.060596","article-title":"Targeted screening for transthyretin amyloid cardiomyopathy in patients with atrial fibrillation.","volume":"146","author":"Prasad","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"hbr230009r15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.006350","article-title":"Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities).","volume":"11","author":"Mou","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2805333\/jamacardiology_selvaraj_2023_br_230009_1690482657.83875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:03:32Z","timestamp":1691593412000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2805333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.1525","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}